It's been a tough year for Novo Nordisk, the Danish pharmaceutical company behind the GLP-1 drugs Ozempic and Wegovy.

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

OMAHA, Neb. (WOWT) - The FDA is cracking down on off brand weight loss products similar to Ozempic. GLP-1 drugs for weight loss like Wegovy or Zepbound were previously in a shortage.

Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

Americans face soaring prescription drug prices, paying far more for medications like Ozempic than patients in Europe or ...

A former head of the US Food and Drug Administration cut his body fat in half using GLP-1 drugs. In his book, he compares the ...

Amy Schumer shares on Instagram that Mounjaro worked wonders for her weight loss and perimenopause symptoms, unlike Ozempic, ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Ozempic, originally for type ... only for managing diabetes but also for appetite regulation and weight loss. #OzempicJourney: How a diabetes drug became a social media weight loss fad Despite ...

Scientists say they may have discovered a natural version of Ozempic that can replicate the effects of popular weight loss ...

Generic versions of Ozempic, Wegovy ... Ultimately, it depends on how much the FDA enforces its regulation. In February, Hims & Hers made the case for the “personalization” of weight-loss ...